BVita Therapeutics, led by CEO Douglas Falk, recently completed a $31 million series B funding round. Douglas Falkaltimore's Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.

Image: Vita Therapeutics, led by CEO Douglas Falk, recently completed a $31 million series B funding round. - Douglas Falk